Under the collaboration, Lonza will develop and manufacture demcizumab, anti-Notch 2/3 projects, anti-Fzd7, anti-Notch, anti-DLL4/VEGF Bi-Specific, including many other monoclonal antibodies at its mammalian manufacturing facility in Slough, UK.
The contract also includes a multi-product GS license with access to Lonza’s GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.
Lonza custom manufacturing COO Stephan Kutzer said, "This multi-product contract and GS license agreement demonstrate Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle."
OncoMed process development vice president Michael Mulkerrin said, "Over the years, Lonza’s expertise has been invaluable in helping us rapidly advance our growing anti-cancer stem cell pipeline."